The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...

The company states: “Novo Nordisk (NVO) A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 ...

Jan 8 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for ...

European shares ended Wednesday's choppy session higher, as a rise in healthcare companies GSK and Novo Nordisk following ...

As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this pharmaceutical revolution. Medicare price negotiations may tighten ...

As of 11 a.m. ET, shares of Novo Nordisk (NYSE: NVO) are down 4.2%, and Hims & Hers Health (NYSE: HIMS) stock is getting walloped for a 5.8% loss. In contrast, shares of Viking Therapeutics ...

Novo Nordisk's experimental obesity drug amycretin demonstrated promising weight loss results in an early-stage trial, with participants losing 22% of their body weight in 36 weeks. This news boosted ...

Novo Nordisk NOVO.B-0.18%decrease; red down pointing triangle expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...